Meningitec: primary immunisation schedule reduced to two doses

The Summary of Product Characteristics for Wyeth's meningitis C vaccine, Meningitec, has been revised to include a two-dose primary immunisation schedule instead of the three-dose schedule recommended previously.

Meningitec is licensed for active immunisation of children from two months of age, adolescents and adults for the prevention of invasive disease caused by serogroup C.

The revised dosing recommendations for children aged two years and over state that two 0.5mL doses should be given, the first not earlier than two months of age, and with a minimum two-month interval between the two.

It is recommended that a booster dose is given after completion of this primary immunisation series, the timing of which should be in accordance with available official recommendations.

The recommended dose in children over 12 months, adolescents and adults, remains as a single dose of 0.5mL.

Meningitec should be administered by intramuscular injection, preferably in the anterolateral thigh in infants and in the deltoid region in older children, adolescents and adults. Gluteal injection is not recommended.

View Meningitec drug record

Further information available from: Wyeth Laboratories


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases